Halozyme Therapeutics, Inc. — FY2020 Form 10-K
Reporting period: Fiscal year ended December 31, 2020. This is an annual filing, not a standalone Q4 report; quarterly figures are unaudited. Halozyme is a biotechnology platform company that licenses its ENHANZE drug-delivery technology, based on rHuPH20, and sells Hylenex.
Financial results and liquidity
| Metric | FY2020 | FY2019 |
|---|---|---|
| Total revenue | $267.6 million | $196.0 million |
| Operating income (loss) | $144.3 million | $(67.6) million |
| Net income (loss) | $129.1 million | $(72.2) million |
| Diluted EPS | $0.91 | $(0.50) |
| Cash from operating activities | $55.5 million | $(85.4) million |
| Cash, equivalents and marketable securities at year-end | $368.0 million | $421.3 million |
| Working capital at year-end | $133.4 million | $457.8 million |
Revenue increased about 37%. Royalties rose to $88.6 million from $69.9 million, while product sales declined to $56.0 million from $66.0 million, mainly because 2019 included a large one-time bulk rHuPH20 order. Revenue under collaboration agreements more than doubled to $123.0 million from $60.0 million, reflecting license and milestone revenue. Hylenex sales were essentially flat at $17.0 million.
Product sales gross profit was approximately $12.6 million, or 22.5% of product sales, versus $20.5 million, or 31.0%, in 2019. The company reported $144.3 million of operating income on a revenue mix that included substantial collaboration fees and milestones; this is not a directly comparable product-sales margin. Interest expense rose to $20.4 million from $11.6 million, largely due to accounting interest on the convertible notes.
Quarter four revenue was $121.7 million and net income was $73.2 million. Q4 revenue included $57.0 million of collaboration revenue; results therefore reflect significant milestone and license timing.
Debt, capital allocation and balance sheet
At year-end, the company had $460.0 million principal amount of 1.25% convertible senior notes due December 2024, recorded at a net carrying amount of $397.2 million. Because the conditional conversion feature was triggered, the notes were classified as current, contributing to the decline in reported working capital. In January 2021, Halozyme said it would settle note principal in cash upon conversion; any conversion value above principal may be settled in shares. The royalty-backed loan was repaid in June 2020, and the Oxford/SVB loan had been repaid in 2019.
Halozyme repurchased 6.5 million shares for $150.0 million during 2020. Since its 2019 program began, it had repurchased $350.0 million of the authorized $550.0 million. Management said existing cash and marketable securities were expected to fund operations for at least the next 12 months.
Material changes, outlook and risks
- Growth in royalties was driven in part by the 2020 U.S. and European launches of Janssen’s subcutaneous DARZALEX products; Roche’s Phesgo received U.S. and European approvals. These launches and additional milestones helped drive the year’s revenue and profit rebound.
- The company discontinued PEGPH20 after its HALO-301 trial failed to meet the primary overall-survival endpoint in 2019. The resulting shift to an ENHANZE- and Hylenex-focused business reduced R&D and SG&A expenses materially in 2020.
- Management expected royalty revenue to grow with recent partner launches, partly offset by biosimilar effects on mature Roche products. Collaboration revenue and bulk rHuPH20 sales may fluctuate with partner milestones, development activity and purchase needs; the filing gives no specific financial guidance.
- COVID-19 caused remote work and restrictions on travel, and elective-surgery cancellations temporarily affected Hylenex sales. Management reported no identified material COVID-related delay to ENHANZE milestone revenue at the time, but warned that effects on trials, partners, regulators and supply chains remained uncertain.
- Key risks include dependence on partners for product development and commercialization; regulatory, clinical and market-acceptance uncertainty; reliance on a limited number of contract manufacturers; concentration of receivables and revenue among major partners; intellectual-property challenges; and convertible-debt liquidity or dilution exposure.
- Halozyme reported no material legal proceedings. The independent auditor gave an unqualified opinion on the financial statements and internal control over financial reporting.
Investor verification points
- Separate recurring royalties and product revenue from milestone, target-license and other collaboration revenue; verify the timing and probability assumptions behind variable consideration.
- Track DARZALEX, Phesgo and other partner products’ launches, sales, royalty contribution and potential biosimilar erosion.
- Assess the $460.0 million convertible-note principal, current classification, cash settlement terms and resulting liquidity or dilution implications.
- Monitor cash conversion: operating cash flow improved to $55.5 million, while accounts receivable and inventories increased substantially year over year.
- Verify progress on the company’s post-PEGPH20 strategy, partner pipeline milestones, manufacturing capacity and any continuing COVID-related effects.